Prognostic Biomarkers in Malignant Melanoma Lunch Session Sponsored by Castle Biosciences, Inc.


Gold Rush Ballroom April 20, 2017 12:35 pm – 1:45 pm

Session Chair: Jonathan Zager, MD

Session Chair: Jonathan Zager, MD, Moffitt Cancer Center, Tampa, USA

Box Lunches will be provided, (non-CME). Sponsored by Castle Biosciences, Inc.

Castle Biosciences, Inc. is a provider of molecular diagnostics to improve cancer treatment decisions. The DecisionDx™-Melanoma test assesses a melanoma patient’s unique tumor biology and resulting metastatic risk to aid treatment planning and optimize patient outcomes (www.SkinMelanoma.com; www.CastleBiosciences.com). Based near Houston TX with CAP-accredited, CLIA-certified laboratory facilities in Phoenix AZ.

There are 0 comments